Psoriasis Update: Can We Finally Say Cure?

Andrew Blauvelt, MD, MBA, an Investigator at Oregon Medical Research Center in Portland, shares data from the Knock-out study showing that high induction doses of risankizumab (Skyrizi, AbbVie) can put patients with moderate-to-severe plaque psoriasis into long-term remission.

Hive Mind: Advances in Treating Chronic Spontaneous Urticaria

Dermatologists are taking back the management of chronic spontaneous urticaria thanks to the advent of targeted therapies that break down the disease, shut off itching, and put patients into remission. Jason Hawkes, MD, MS, a dermatologist in Rocklin, CA, discusses this new treatment paradigm.

HS: The Disease of the Decade

Thanks to new treatments and a full pipeline, hidradenitis suppurativa (HS) is finally getting its due. Raj Chovatiya, MD, PhD, an Assistant Professor of Dermatology at the Northwestern University Feinberg School of Medicine in Chicago, discusses what these new and coming treatments mean for HS patients and the dermatologists who treat them.

Can PsA Be Prevented in Psoriasis Patients?

Blocking IL-23 may be the best mechanism of action for trying to prevent new-onset psoriatic arthritis (PsA) in psoriasis patients. Bruce Strober, MD, PhD, a Clinical Professor of Dermatology at Yale University School of Medicine and co-founder of Central Connecticut Dermatology, reviews the data on this novel concept.

Alopecia Areata Update

Jerry Shapiro, MD, Professor and Director of Disorders of the Hair and Scalp at New York University’s Grossman School of Medicine in New York City, discusses how ritlecitinib (Litfulo, Pfizer) and baricitinib (Olumiant, Lilly) are improving the lives of people with alopecia areata.

Revealed: Game-changing Non-surgical Cosmetic Combinations

Synergistic combinations of energy-based devices, neuromodulators, and fillers are taking nonsurgical cosmetic results to the next level. Suneel Chilukuri, MD, Director of Cosmetic Surgery at Refresh Dermatology in Houston, explains how today’s minimally invasive combinations achieve aesthetic results that rival those once only seen with surgery.

From the Podium to Practice: Managing Advanced CSCC in 2024

Emily S. Ruiz, MD, MPH, Academic Director of Mohs and Dermatologic Surgery Center and the Director of the High-Risk Skin Cancer Clinic at the Dana-Farber Brigham Cancer Center in Boston, discusses key prognostic factors and new treatment options for cutaneous squamous cell carcinoma.

All Clear: Integrating New Psoriasis Topicals Into Practice

New non-steroidal topical psoriasis therapies are changing the way dermatologists treat psoriasis. Linda F. Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Hospital in Detroit, explains how, when, and why she uses these new options.

New Drugs in Dermatology: A Review​

Derm Digest medical editor Ted Rosen, MD, a Professor of Dermatology at Baylor College of Medicine in Houston, discusses the spate of recent U.S. Food and Drug Administration approvals in dermatology from Cabtreo for acne and two new therapies for molluscum contagiosum to secukinumab (Cosentyx, Novartis) for hidradenitis suppurativa, and a new device to aid […]